Sanofi buys hepatitis B vaccine maker Dynavax for $2.2B; gets CRL for MS drug
Elizabeth Cairns / endpoints - Sanofi is set to supplement its vaccine offering with the acquisition of Dynavax Technologies for $2.2 billion in cash, the companies said Wednesday. Separately, Sanofi said the ...
AI Summary: Two separate reports confirm that Sanofi has completed a $2.2 billion deal to acquire Dynavax Technologies. This strategic move strengthens Sanofi’s vaccine lineup by adding a commercially proven hepatitis B vaccine and a clinical‐stage shingles candidate, positioning the company for enhanced market competitiveness amid global pressures.
Related Stories
Merck Eyes $30B Deal for Revolution Medicines Acquisition / 5 months
Merck acquires Cidara’s preventive flu drug for $9.2B / 7 months
Vanderbilt’s experimental C. diff vaccine shows promising protection / 4 months
Nasal-spray ‘universal’ vaccine protects mice from many respiratory threats / 4 months
Biogen announces $5.6B acquisition of Apellis Pharma / 3 months
Gilead buys Ouro Medicines for about $1.68–1.7B to bolster autoimmune pipeline / 3 months
Novartis closes Avidity deal; Atrium Therapeutics spinout launches / 4 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Product Recall, Pediatric Oncology, Price Transparency, FDA and look for the RSS link.
StackHealth Time Machine